Modality
Multispecific
MOA
VEGFi
Target
FLT3
Pathway
Apoptosis
DravetT2DCrohn's
Development Pipeline
Preclinical
~May 2010
→ ~Aug 2011
Phase 1
~Nov 2011
→ ~Feb 2013
Phase 2
~May 2013
→ ~Aug 2014
Phase 3
~Nov 2014
→ ~Feb 2016
NDA/BLA
~May 2016
→ ~Aug 2017
Approved
Nov 2017
→ Oct 2030
ApprovedCurrent
NCT03676880
1,286 pts·Dravet
2025-10→TBD·Terminated
NCT06160553
241 pts·Dravet
2020-08→2030-10·Recruiting
NCT04914482
2,724 pts·Crohn's
2024-08→2025-07·Completed
+1 more trial
6,257 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-07-218mo agoPh3 Readout· Crohn's
2026-04-223w awayPh3 Readout· Crohn's
2030-10-284.6y awayPh3 Readout· Dravet
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Active
Approved
Recruit…
Approved
Complet…
Approved
Termina…
Catalysts
Ph3 Readout
2025-07-21 · 8mo ago
Crohn's
Ph3 Readout
2026-04-22 · 3w away
Crohn's
Ph3 Readout
2030-10-28 · 4.6y away
Dravet
RecruitingActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03676880 | Approved | Dravet | Terminated | 1286 | DAS28 |
| NCT06160553 | Approved | Dravet | Recruiting | 241 | DAS28 |
| NCT04914482 | Approved | Crohn's | Completed | 2724 | HbA1c |
| NCT03804253 | Approved | Crohn's | Active | 2006 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Gozeosocimab | Illumina | Phase 2 | BCMA |